Wu Henry Yim
Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Clin Immunol. 2009 Feb;130(2):111-22. doi: 10.1016/j.clim.2008.08.028. Epub 2008 Oct 19.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by aberrant immune responses against intracellularly derived self antigens. Treatment for SLE relies on the use of aggressive immunosuppressants and steroids that are nonspecific and can cause serious adverse effects. The observation that a systemic immune tolerance to self antigens or generation of regulatory T cells may follow mucosal (nasal or oral) exposure to self proteins or monoclonal antibody against CD3 respectively suggests that induction of mucosal tolerance offers the basis of a side effect-free therapy that could re-establish the ability to distinguish self from non-self and restore peripheral tolerance in individuals susceptible to developing autoimmune diseases. Here I review studies on mucosal tolerance in autoimmune diseases and discuss the therapeutic potential of inducing tolerance for the treatment of SLE.
系统性红斑狼疮（SLE）是一种自身免疫性疾病，其特征是针对细胞内源性自身抗原的异常免疫反应。SLE的治疗依赖于使用具有侵袭性的免疫抑制剂和类固醇，这些药物是非特异性的，并且会引起严重的副作用。分别通过黏膜（鼻腔或口腔）接触自身蛋白或抗CD3单克隆抗体后，可能会出现对自身抗原的全身免疫耐受或调节性T细胞的产生，这一观察结果表明，诱导黏膜耐受为一种无副作用的治疗方法提供了基础，这种方法可以重新建立区分自身与非自身的能力，并恢复易患自身免疫性疾病个体的外周耐受。在此，我综述了自身免疫性疾病中黏膜耐受的研究，并讨论了诱导耐受治疗SLE的治疗潜力。
